表紙:多嚢胞性卵巣症候群(PCOS)の世界市場(2021年~2027年)
市場調査レポート
商品コード
1025371

多嚢胞性卵巣症候群(PCOS)の世界市場(2021年~2027年)

Polycystic Ovary Syndrome (PCOS) Market 2021-2027

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.72円
多嚢胞性卵巣症候群(PCOS)の世界市場(2021年~2027年)
出版日: 2021年06月30日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

多嚢胞性卵巣症候群(PCOS)の市場規模は、予測期間中に約4.0%というかなりのCAGRで成長すると予測されています。女性におけるPCOSの有病率の上昇が、市場の成長を促す主な要因となっています。また、PCOS治療薬の入手可能性についての患者層の認識が高まっていることも、PCOS治療薬市場の成長を後押ししています。PCOSは、体重の急激な増加、ホルモンの変化、生理不順、不妊などの主な症状を有しています。PCOSに特異的な治療法はありませんが、これらの症状を治療するための薬剤や治療薬は数多くあります。そのため、サノフィ、ノバルティス、テバ・ファーマシューティカル・インダストリーズ・リミテッドなどの市場リーダーは、PCOSの新しい薬剤や治療法の開発に注力しています。さらに、PCOS治療薬に対する規制当局の承認の増加や、併用薬の採用が増加していることも、市場の成長を阻害しています。一方、研究開発活動への高額な投資、PCOSに関する認識を広めるための政府の取り組みの増加、技術の進歩は、予測期間中の市場をさらに牽引すると考えられます。

PCOSの世界市場は、薬剤タイプ、診断、治療、流通チャネルに基づいて分類されています。薬剤タイプ別では、利尿薬、インスリン抵抗性改善薬、抗アンドロゲン薬、抗うつ薬、オルニチンデカルボキシラーゼ阻害薬、抗肥満薬、経口避妊薬に分類されています。診断別では、市場は超音波検査、骨盤検査、血液検査に分類されます。一方、治療別では、卵巣楔状切除術、腹腔鏡下卵巣掘削術、鍼灸治療に分類されます。PCOSの有病率の上昇に伴い、腹腔鏡下卵巣掘削術が市場を支配すると予想されます。PCOSの世界市場は、流通チャネル別では、病院薬局、小売薬局(オンラインおよびオフライン)、不妊治療クリニックに分類されています。

地理的には、北米、欧州、アジア太平洋地域、その他の地域に分けられます。予測期間中は、北米と欧州が市場を支配すると予想されます。この地域では、肥満がPCOSの主な原因の一つであることから、PCOS治療薬や治療法に対する需要が高く、市場成長の原動力となっています。また、政府による医療分野での償還政策や、PCOSの早期診断に関する人々の意識も、この地域の市場展望を後押ししています。さらに、アジア太平洋地域は、予測期間中、世界の多嚢胞性卵巣症候群市場で最も速い成長を示すと予測されています。大規模な患者層の存在、PCOSの有病率の増加に関する政府の啓発プログラム、PCOSに対する費用対効果の高い治療法の進歩などが、アジア太平洋地域におけるPCOS市場の成長を促進する主な要因となっています。同市場の主要企業は、アボット・ラボラトリーズ、アストラゼネカPLC、バイエルAG、ブリストル・マイヤーズスクイブ社、フェリング・ファーマシューティカルズ、メルク・アンド・カンパニー・インク、ノバルティスAG、テバ・ファーマシューティカル・インダストリーズ・リミテッドなどです。

当レポートでは多嚢胞性卵巣症候群(PCOS)の世界市場を調査し、市場の概要、市場の成長要因および阻害要因の分析、市場機会、薬剤タイプ・診断・治療・流通チャネル・地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向

第3章 競合情勢

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
  • 重要な戦略分析
  • キープレーヤーに対するCOVID-19の影響

第4章 市場の決定要因

  • 成長要因
  • 抑制要因
  • 市場機会

第5章 市場細分化

  • 薬剤タイプ別
    • 利尿薬
    • インスリン感作剤
    • 抗アンドロゲン
    • 抗うつ剤
    • オルニチンデカルボキシラーゼ阻害剤
    • 抗肥満
    • 経口避妊薬
  • 診断タイプ別
    • 超音波
    • 内診
    • 血液検査
  • 治療タイプ別
    • 卵巣楔状切除術
    • 腹腔鏡下卵巣穿孔
  • 流通チャネル別
    • 病院薬局
    • 小売薬局(オンラインおよびオフライン)
    • 不妊治療クリニック

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • ロシア
    • その他欧州
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 南朝鮮
    • その他アジア太平洋地域
  • その他の地域
    • ラテンアメリカ
    • 中東とアフリカ

第7章 企業プロファイル

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • AVA Science Inc.
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Dexa Medica(Dexa Group)
  • Ferring B.V.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Millendo Therapeutics, Inc.
  • MyOva
  • Novartis AG
  • PCOS Diva LLC
  • Pharmasure Ltd.
  • Sanofi SA
  • Sneha Natura
  • Teva Pharmaceutical Industries Ltd.
  • The Himalaya Drug Co.
  • Theralogix, LLC
図表

LIST OF TABLES

  • 1. GLOBAL PCOSMARKET RESEARCH AND ANALYSIS BY DRUG TYPE,2020-2027 ($ MILLION)
  • 2. GLOBAL DIURETICS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL INSULIN SENSITIZING AGENTS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL ANTIANDROGENS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL ANTI-DEPRESSANTS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL ORNITHINE DECARBOXYLASE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL ANTI-OBESITY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL PCOSMARKET RESEARCH AND ANALYSIS BYDIAGNOSIS TYPE, 2020-2027 ($ MILLION)
  • 10. GLOBAL ULTRASOUND FOR PCOSMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL PELVIC EXAM FOR PCOSMARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 12. GLOBAL BLOOD TEST FOR PCOSMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL PCOSMARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
  • 14. GLOBAL OVARIAN WEDGE RESECTION IN PCOSMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 15. GLOBAL LAPAROSCOPIC OVARIAN DRILLING IN PCOSMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 16. GLOBAL ACUPUNCTURE IN PCOSMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 17. GLOBAL PCOS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 18. GLOBAL HOSPITAL PHARMACIES IN PCOS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 19. GLOBAL RETAIL PHARMACIES (ONLINE AND OFFLINE) IN PCOS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 20. GLOBAL FERTILITY CLINICS IN PCOS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 21. NORTH AMERICAN PCOSMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 22. NORTH AMERICAN PCOSMARKET RESEARCH AND ANALYSIS BY DRUG TYPE,2020-2027 ($ MILLION)
  • 23. NORTH AMERICAN PCOSMARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TYPE, 2020-2027 ($ MILLION)
  • 24. NORTH AMERICAN PCOSMARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
  • 25. NORTH AMERICAN PCOS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 26. EUROPEAN PCOSMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 27. EUROPEAN PCOSMARKET RESEARCH AND ANALYSIS BYDRUG TYPE,2020-2027 ($ MILLION)
  • 28. EUROPEAN PCOSMARKET RESEARCH AND ANALYSIS BYDIAGNOSIS TYPE, 2020-2027 ($ MILLION)
  • 29. EUROPEAN PCOSMARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
  • 30. EUROPEAN PCOS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 31. ASIA-PACIFIC PCOSMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 32. ASIA-PACIFIC PCOSMARKET RESEARCH AND ANALYSIS BYDRUG TYPE,2020-2027 ($ MILLION)
  • 33. ASIA-PACIFIC PCOSMARKET RESEARCH AND ANALYSIS BYDIAGNOSIS TYPE,2020-2027 ($ MILLION)
  • 34. ASIA-PACIFIC PCOSMARKET RESEARCH AND ANALYSIS BYTREATMENT TYPE, 2020-2027 ($ MILLION)
  • 35. ASIA-PACIFIC PCOS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 36. REST OF THE WORLD PCOSMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 37. REST OF THE WORLD PCOSMARKET RESEARCH AND ANALYSIS BYDRUG TYPE,2020-2027 ($ MILLION)
  • 38. REST OF THE WORLD PCOSMARKET RESEARCH AND ANALYSIS BYDIAGNOSIS TYPE,2020-2027 ($ MILLION)
  • 39. REST OF THE WORLD PCOSMARKET RESEARCH AND ANALYSIS BYTREATMENT TYPE, 2020-2027 ($ MILLION)
  • 40. REST OF THE WORLD PCOS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)

LIST OF FIGURES

1. IMPACT OF COVID-19 ON GLOBAL PCOSMARKET, 2020-2027 (% MILLION)

2. IMPACT OF COVID-19 ON GLOBAL PCOSMARKET BY SEGMENT, 2020-2027 (% MILLION)

  • 3. RECOVERY OF GLOBAL PCOSMARKET, 2020-2027 (%)
  • 4. GLOBAL PCOSMARKET SHARE BYDRUG TYPE,2020 VS 2027 (%)
  • 5. GLOBAL PCOSMARKET SHARE BYDIAGNOSIS TYPE,2020 VS 2027 (%)
  • 6. GLOBAL PCOSMARKET SHARE BY TREATMENT TYPE,2020 VS 2027 (%)
  • 7. GLOBAL PCOSMARKET SHARE BY DISTRIBUTION CHANNEL,2020 VS 2027 (%)
  • 8. GLOBAL PCOSMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL DIURETICS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL INSULIN SENSITIZING AGENTS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL ANTIANDROGENS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL ANTI-DEPRESSANTS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL ORNITHINE DECARBOXYLASE INHIBITORS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL ANTI-OBESITY MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 15. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 16. GLOBAL ULTRASOUND FOR PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 17. GLOBAL PELVIC EXAM FOR PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 18. GLOBAL BLOOD TEST FOR PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 19. GLOBAL OVARIAN WEDGE RESECTION IN PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 20. GLOBAL LAPAROSCOPIC OVARIAN DRILLING IN PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 21. GLOBAL ACUPUNCTURE IN PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 22. GLOBAL HOSPITAL PHARMACIES IN PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 23. GLOBAL RETAIL PHARMACIES (ONLINE AND OFFLINE) IN PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 24. GLOBAL FERTILITY CLINICS IN PCOS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 25. UK PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 26. FRANCE PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 27. GERMANY PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 28. ITALY PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 29. SPAIN PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 30. REST OF EUROPE PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 31. INDIA PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 32. CHINA PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 33. JAPAN PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 34. SOUTH KOREA PCOSMARKET SIZE, 2020-2027 ($ MILLION)
  • 35. REST OF ASIA-PACIFIC PCOSMARKET SIZE, 2020-2027 ($ MILLION)

36. REST OF THE WORLD PCOSMARKET SIZE, 2021-2027($ MILLION

目次
Product Code: OMR2023787

Global Polycystic Ovary Syndrome (PCOS) Market Size, Share & Trends Analysis Report By Drug Type (Diuretics, Insulin Sensitizing Agents, Antiandrogens, Anti-Depressants, Ornithine Decarboxylase Inhibitors, and Others), By Diagnosis (Ultrasound, Pelvic Exam, and Others) By Treatment (Ovarian Wedge Resection, Laparoscopic Ovarian Drilling, and Others) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies (Online And Offline), And Fertility Clinics) Forecast, 2021-2027

The global market for PCOS is projected to have a considerable CAGR of around 4.0% during the forecast period. The rising prevalence of PCOS in women is the major factor driving the growth of the market. Additionally, growing awareness among the patient population about the availability of the treatment is fueling the growth of the PCOS treatment market. The sudden gain in weight, hormonal changes, irregular periods, and infertility are some of the major symptoms associated with PCOS. There is no specific treatment for PCOS,  however, there are numerous drugs and therapeutics used to treat these symptoms. Therefore, market leaders such as Sanofi, Novartis, Teva Pharmaceutical Industries Limited are focusing on developing novel drugs and treatments for PCOS. Moreover, the growing adoption of combination drugs and growing regulatory approvals to the drugs for PCOS is also exculpating the market growth. Whereas, the high investment for the R&D activities, and growing government initiatives to spread awareness about PCOS, and technological advancements are further projected to drive the market during the forecast period.

The Global PCOS market is segmented based on drug type, diagnosis, treatment, and distribution channel. Based on drug type, the market is segmented into diuretics, insulin-sensitizing agents, antiandrogens, anti-depressants, ornithine decarboxylase inhibitors, anti-obesity, and oral contraceptive pills. the insulin-sensitizing agents hold a major share owing to the wide adoption of the drug for the treatment of insulin resistance, to prevent diabetes which is one of the major causes of PCOS. Based on the diagnosis, the market is further classified into ultrasound, pelvic exam, and blood test. Whereas, the treatment segment is categorized into ovarian wedge resection, laparoscopic ovarian drilling, and acupuncture. Laparoscopic ovarian drilling is expected to dominate the market owing to the rising prevalence of PCOS. Similarly, based on distribution channels, the global PCOS market is segmented into hospital pharmacies, retail pharmacies (online and offline), and fertility clinics.

Geographically the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America and Europe are expected to dominate the market during the forecast period.  The presence of obese women population in this region is creating a high demand for PCOS drugs and treatments, as obesity is one of the major causes of PCOS, which in turn, driving the market growth. reimbursement policies by the government in the healthcare sector and awareness amongst the population regarding the early diagnosis of PCOS are also boosting the market prospects in the regions. Furthermore, the Asia-Pacific is projected to exhibit the fastest growth in the global polycystic ovary syndrome market over the forecast period. The presence of a large patient pool, government awareness programs regarding the growing prevalence of PCOS, and advancement in cost-effective treatments for PCOS are the major factors driving the growth of the PCOS market in the Asia-pacific region. The key players of the market are Abbott Laboratories, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co., Ferring Pharmaceuticals, Merck & Co., Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., among others.

Research Methodology

The market study of the global polycystic ovary syndrome (PCOS) market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Polycystic ovary syndrome (PCOS) Market Research and Analysis by Product Type
  • Global Polycystic ovary syndrome (PCOS) Market Research and Analysis by Material
  • Global Polycystic ovary syndrome (PCOS) Market Research and Analysis by End-user

The Report Covers

  • Comprehensive research methodology of the global polycystic ovary syndrome (PCOS) market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global polycystic ovary syndrome (PCOS) market.
  • Insights about market determinants that are stimulating the global polycystic ovary syndrome (PCOS) market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the GlobalPCOS Industry
  • Recovery Scenario of Global PCOS Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on key players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global PCOS Market, ByDrug Type
    • 5.1.1. Diuretics
    • 5.1.2. Insulin Sensitizing Agents
    • 5.1.3. Antiandrogens
    • 5.1.4. Anti-Depressants
    • 5.1.5. Ornithine Decarboxylase Inhibitors
    • 5.1.6. Anti-Obesity
    • 5.1.7. Oral Contraceptive Pills
  • 5.2. Global PCOSMarket, By Diagnosis Type
    • 5.2.1. Ultrasound
    • 5.2.2. Pelvic Exam
    • 5.2.3. Blood Test
  • 5.3. Global PCOSMarket, By Treatment Type
    • 5.3.1. Ovarian Wedge Resection
    • 5.3.2. Laparoscopic Ovarian Drilling
    • 5.3.3. Acupuncture
  • 5.4. Global PCOSMarket, By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies (Online and Offline)
    • 5.4.3. Fertility Clinics

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Russia
    • 6.2.7. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korean
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World
    • 6.4.1. Latin America
    • 6.4.2. Middle East& Africa

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. Astellas Pharma Inc.
  • 7.3. AstraZeneca plc
  • 7.4. AVA Science Inc.
  • 7.5. Bayer AG
  • 7.6. Bristol-Myers Squibb Co.
  • 7.7. Dexa Medica (Dexa Group)
  • 7.8. Ferring B.V.
  • 7.9. GlaxoSmithKline plc
  • 7.10. Merck & Co., Inc.
  • 7.11. Millendo Therapeutics, Inc.
  • 7.12. MyOva
  • 7.13. Novartis AG
  • 7.14. PCOS Diva LLC
  • 7.15. Pharmasure Ltd.
  • 7.16. Sanofi SA
  • 7.17. Sneha Natura
  • 7.18. Teva Pharmaceutical Industries Ltd.
  • 7.19. The Himalaya Drug Co.
  • 7.20. Theralogix, LLC